グローバルにおけるデング熱ワクチン市場：事業機会分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 24
3.2 Symptoms 27
3.3 Prognosis 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 31
4.3 Global Trends 34
4.3.1 Incidence and Geographic Distribution 34
4.3.2 Dengue Periodic and Seasonal Patterns 36
4.3.3 Dengue Serotypes 37
4.4 Forecast Methodology 38
4.4.1 Sources Used 40
4.4.2 Sources Not Used 43
4.4.3 Forecast Assumptions and Methods 43
4.5 Epidemiological Forecast for Dengue (2013-2023) 46
4.5.1 Reported Laboratory-Confirmed Dengue Cases 46
4.5.2 Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases 48
4.5.3 Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases 50
4.5.4 Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue 51
4.6 Discussion 52
4.6.1 Epidemiological Forecast Insight 52
4.6.2 Limitations of the Analysis 53
4.6.3 Strengths of the Analysis 54
5 Current Surveillance, Prevention, and Control Measures 55
5.1 Overview 55
5.2 Brazil 61
5.2.1 Surveillance and Diagnosis 61
5.2.2 Vector Control 61
5.2.3 Immunization Recommendations and Infrastructure 62
5.3 India 64
5.3.1 Surveillance and Diagnosis 65
5.3.2 Vector Control 65
5.3.3 Immunization Recommendations and Infrastructure 66
5.4 Mexico 68
5.4.1 Surveillance and Diagnosis 68
5.4.2 Vector Control 69
5.4.3 Immunization Recommendations and Infrastructure 70
5.5 Singapore 72
5.5.1 Surveillance and Diagnosis 72
5.5.2 Vector Control 73
5.5.3 Immunization Recommendations and Infrastructure 73
5.6 Thailand 75
5.6.1 Surveillance and Diagnosis 75
5.6.2 Vector Control 76
5.6.3 Immunization Recommendations and Infrastructure 76
6 Unmet Needs Assessment and Opportunity Analysis 79
6.1 Overview 79
6.2 Unmet Needs Analysis 81
6.2.1 Unmet Need: Safe and Efficacious Vaccines 81
6.2.2 Unmet Need: An Improved Understanding of Dengue Immunity 83
6.2.3 Unmet Need: Reliable Immunological Correlates of Protection 83
6.2.4 Unmet Need: Country-Specific Immunization Program Preparedness 84
6.2.5 Unmet Need: Upgraded Vector Control and Surveillance Infrastructures 85
6.2.6 Unmet Need: Improved Diagnostic Tools 86
6.2.7 Unmet Need: High-Quality Animal Models 87
6.3 Opportunity Analysis 88
6.3.1 Opportunity: Develop a Single-Dose Dengue Vaccine 88
6.3.2 Opportunity: Further Elucidate the Role(s) of T Cells in Dengue Immunity 88
6.3.3 Opportunity: Streamline Vaccine Development with Innovative Clinical Trial Design 89
6.3.4 Opportunity: Partner with Public Health Stakeholders to Integrate Vaccines into Multifaceted Dengue Prevention Programs 90
6.3.5 Opportunity: Establish Country-Specific Vaccine Launch Strategies 91
6.3.6 Opportunity: Leverage Diagnostics to Demonstrate Vaccine Effectiveness Post-Licensure 92
7 Research and Development Strategies 93
7.1 Overview 93
7.2 Technological Approaches to Vaccine Development 93
7.2.1 Vaccine Antigen Selection 93
7.2.2 Tetravalent Vaccine Construction 95
7.3 Partnerships, Acquisitions, and Licensing Agreements 97
7.4 Clinical Trial Design 99
7.4.1 Current Clinical Trial Design 99
7.4.2 Inclusion of Representative Patient Populations in Clinical Trials 102
7.4.3 Demonstration of Protective Efficacy 102
7.4.4 Dengue Human Infection Model 103
8 Pipeline Assessment 105
8.1 Overview 105
8.2 Live-Attenuated Vaccines in Clinical Development 110
8.2.1 CYD-TDV 110
8.2.2 DENVax 118
8.2.3 TV-003 123
8.3 Other Vaccines in Clinical Development 129
8.3.1 TDENV-PIV 129
8.3.2 DEN-80E 131
8.4 Vaccines in Preclinical Development 135
9 Pipeline Valuation Analysis 137
9.1 Clinical Benchmarking of Key Pipeline Vaccines 137
9.2 Commercial Benchmarking of Key Pipeline Vaccines 139
9.3 Competitive Assessment 141
9.4 Top-Line Five-Year Forecast 143
9.4.1 Brazil 146
9.4.2 India 147
9.4.3 Mexico 148
9.4.4 Singapore 148
9.4.5 Thailand 149
10 Appendix 150
10.1 Bibliography 150
10.2 Abbreviations 170
10.3 Methodology 174
10.4 Forecasting Methodology 174
10.4.1 Vaccinated Patients 174
10.4.2 Vaccination Coverage Rates 175
10.4.3 Vaccines Included in Each Class 175
10.4.4 Vaccine Launch Dates 175
10.4.5 General Pricing Assumptions 176
10.4.6 Individual Vaccine Assumptions 177
10.4.7 Pricing of Pipeline Vaccines 180
10.5 Physicians and Specialists Included in this Study 183
10.6 About the Authors 185
10.6.1 Analyst 185
10.6.2 Epidemiologist 185
10.6.3 Therapy Area Director 186
10.6.4 Global Head of Healthcare 186
10.7 About GlobalData 187
10.8 Disclaimer 187